- Previous close
8.70 - Open
8.60 - Bid 8.90 x --
- Ask 9.10 x --
- Day's range
8.60 - 9.10 - 52-week range
5.17 - 56.36 - Volume
6,857 - Avg. Volume
25,118 - Market cap (intra-day)
62.2M - Beta (5Y monthly) 0.69
- PE ratio (TTM)
-- - EPS (TTM)
-93.94 - Earnings date --
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
--
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision. Prostatype Genomics AB (publ) was incorporated in 2007 and is based in Solna, Sweden.
www.prostatypegenomics.com6
Full-time employees
December 31
Fiscal year ends
Sector
Industry
Recent news: PROGEN.ST
View morePerformance overview: PROGEN.ST
Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is .
YTD return
1-year return
3-year return
5-year return
Compare to: PROGEN.ST
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: PROGEN.ST
View moreValuation measures
Market cap
62.20M
Enterprise value
71.19M
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
7.00
Price/book (mrq)
4.68
Enterprise value/revenue
69.52
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
0.00%
Return on assets (ttm)
-71.11%
Return on equity (ttm)
-192.04%
Revenue (ttm)
4.12M
Net income avi to common (ttm)
-40.54M
Diluted EPS (ttm)
-93.94
Balance sheet and cash flow
Total cash (mrq)
1.78M
Total debt/equity (mrq)
--
Levered free cash flow (ttm)
-21.85M